静脉注射免疫球蛋白预防复发性自然流产：欧洲经验
Intravenous immunoglobulin in the prevention of recurrent spontaneous abortion: the European experience.
作者信息
Christiansen O B
机构信息
Department of Obstetrics and Gynecology, Aalborg Hospital, Denmark.
出版信息
Am J Reprod Immunol. 1998 Feb;39(2):77-81. doi: 10.1111/j.1600-0897.1998.tb00338.x.
PROBLEM
Clinical trials of the use of intravenous immunoglobulin (IvIg) in the treatment of recurrent spontaneous abortion (RSA) in Europe were reported and discussed.
METHOD OF STUDY
A search of the published literature, combined with our own published and unpublished results, was performed.
RESULTS
Two placebo-controlled trials have been concluded in Europe. One trial found high but equal success rates in both the IvIg and the placebo group. Another trial found that IvIg treatment may increase the success rate by 24% compared with placebo but that the result was not statistically significant, which might be due to the small number of patients. Reasons for the diverse results of the two trials were discussed.
CONCLUSION
More and larger placebo-controlled trials of IvIg treatment in RSA are needed before drawing definitive conclusions.
问题
欧洲报道并讨论了静脉注射免疫球蛋白（IvIg）用于治疗复发性自然流产（RSA）的临床试验。
研究方法
检索已发表的文献，并结合我们自己已发表和未发表的结果进行研究。
结果
欧洲已完成两项安慰剂对照试验。一项试验发现，IvIg组和安慰剂组的成功率都很高且相当。另一项试验发现，与安慰剂相比，IvIg治疗可能使成功率提高24%，但结果无统计学意义，这可能是由于患者数量较少。讨论了两项试验结果不同的原因。
结论
在得出明确结论之前，需要进行更多、规模更大的IvIg治疗RSA的安慰剂对照试验。
Zotero 插件